EGFR and head and neck squamous cell carcinoma: Besides inhibiting the EGFR pathway, anti-EGFR mAbs may exert anti-tumour effects through ADCC (110). This is the case of cetuximab, a chimeric IgG1 mAb directed to the extracellular domain of the EGFR, which has been approved to treat KRAS wild-type metastatic CRC (mCRC) (111) and HNSCC (112).